Tuesday, March 31, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

BrainChip Secures Key Licensing Agreement for Akida-2 Technology

Rodolfo Hanigan by Rodolfo Hanigan
March 31, 2026
in AI & Quantum Computing, Semiconductors, Tech & Software, Trading & Momentum
0
BrainChip Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

The neuromorphic computing specialist BrainChip has announced a significant commercial milestone, signaling a potential turnaround after a prolonged period of limited news. The company entered into a global licensing agreement with EDGEAI over the weekend, granting access to its next-generation Akida-2 technology. This deal reinforces a fundamental recovery that was initially hinted at in the firm’s latest annual revenue figures.

Under the terms of the non-exclusive partnership, EDGEAI receives comprehensive access to the intellectual property underpinning BrainChip’s Akida architecture. The agreement also includes necessary development tools and software components. Financial returns for BrainChip will come through milestone-based payments linked to technical delivery targets. Once EDGEAI begins commercial shipment of its own products, quarterly royalty payments will commence. While management has not yet quantified the precise financial scope, it anticipates substantial long-term revenue streams from resulting product sales.

Should investors sell immediately? Or is it worth buying BrainChip?

Financial Performance Shows Marked Improvement

This new contract aligns with a broader positive shift in the company’s financial trajectory. The annual report for 2025, published in late February, revealed a dramatic 374 percent surge in revenue to $1.89 million. Concurrently, BrainChip managed to narrow its net loss from $24.43 million to $20.47 million. The company also strengthened its balance sheet, with cash reserves growing to $31.71 million. Investor sentiment has responded with cautious optimism. The equity, currently trading at €0.09, is attempting to stabilize following an approximate 28 percent decline over the preceding twelve-month period.

Operational Milestones on the Horizon

Beyond commercial deals, operational execution is now coming into focus. The company reports that its AKD1500 chip has entered the volume production phase, with final silicon expected in the third quarter of 2026. In parallel, development has commenced on the custom AKD2500 project. First prototypes for this chip are also slated for availability in Q3 2026. These technological advancements form the foundation for BrainChip to more broadly address rising demand for ultra-low-power AI applications within the edge computing sector.

Ad

BrainChip Stock: Buy or Sell?! New BrainChip Analysis from March 31 delivers the answer:

The latest BrainChip figures speak for themselves: Urgent action needed for BrainChip investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 31.

BrainChip: Buy or sell? Read more here...

Tags: BrainChip
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Seagate Technology Stock
AI & Quantum Computing

Seagate’s Profitability Surge Driven by AI Storage Demand

March 31, 2026
Horizons Active A.I. Global Equity ETF Stock
AI & Quantum Computing

The AI Fund Manager: An ETF Fully Governed by Algorithm

March 31, 2026
Nvidia Stock
AI & Quantum Computing

Nvidia’s Path to Trillions: The Next-Generation Chip Powering Unprecedented Growth

March 31, 2026
Next Post
Nexus Uranium Stock

Nexus Uranium Shifts Focus to Project Exploration Following Strategic Acquisitions

Orsted Stock

Bank of America Upgrade Ignites Surge in Ørsted Shares

Roche Stock

Roche's Diagnostic Division Gains Momentum with Dual Regulatory Wins

Recommended

Finance_Commercial (2)

Title The Rise in Short Interest and Peer Comparison Assessing Newmonts Market Standing

2 years ago
Astra Energy Stock

Astra Energy Charts Strategic Overhaul Amid Key Project Milestones

2 days ago
TMUS stock news

JMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix

2 years ago
Cryptocurrency Market Capitalization

Stronghold Digital Mining Inc Sets New Records in Bitcoin Mining and Revenue Generation

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Roche’s Diagnostic Division Gains Momentum with Dual Regulatory Wins

Bank of America Upgrade Ignites Surge in Ørsted Shares

Nexus Uranium Shifts Focus to Project Exploration Following Strategic Acquisitions

BrainChip Secures Key Licensing Agreement for Akida-2 Technology

Legal Clarity and Investor Confidence Boost UniCredit Ahead of Key Meeting

Linde Shares Scale Fresh Peak on Institutional Backing and Steady Growth

Trending

CSG Stock
Analysis

Governance Concerns Overshadow Record Performance at Czechoslovak Group

by Jackson Burston
March 31, 2026
0

Despite announcing record annual revenues and a substantial order backlog, shares in the Czechoslovak Group (CSG) have...

Bionxt Solutions Stock

BioNxt Solutions Targets Oral GLP-1 Market with New Drug Delivery Platform

March 31, 2026
Ballard Power Stock

Ballard Power’s Major Contract Fuels Optimistic Growth Forecasts

March 31, 2026
Roche Stock

Roche’s Diagnostic Division Gains Momentum with Dual Regulatory Wins

March 31, 2026
Orsted Stock

Bank of America Upgrade Ignites Surge in Ørsted Shares

March 31, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Governance Concerns Overshadow Record Performance at Czechoslovak Group
  • BioNxt Solutions Targets Oral GLP-1 Market with New Drug Delivery Platform
  • Ballard Power’s Major Contract Fuels Optimistic Growth Forecasts

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com